Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor In a large randomized clinical trial of the use of a β-blocker (esmolol) in patients with severe septic shock, Dr Morelli and colleagues1 demonstrated the ability of esmolol to reduce heart rate. The use of esmolol was associated with a reduction in norepinephrine and fluid requirements and an increase in stroke volume, systemic vascular resistance, and left ventricular stroke work indices. These cardiovascular effects were not only associated with improved respiratory function and metabolic parameters but also with lower 28-day mortality.
Sanfilippo F, Santonocito C, Maybauer MO. Short-Acting β-Blocker Administration in Patients With Septic Shock. JAMA. 2014;311(7):736-737. doi:10.1001/jama.2014.315